Search Within

Michal F Segal

Formats
  1. Meeting Abstract (10)
  2. Journal Article (5)
Groups
  1. Department of Medicine (15)
  2. Gastrointestinal Oncology Service (15)
  3. Solid Tumor Oncology Division (15)
  4. Center for Pancreatic Cancer Research (14)
  5. Biostatistics Service (9)
  6. Epidemiology and Biostatistics (9)

More Groups

People
  1. Marinela Capanu (9)
  2. David Kelsen (6)
  3. Ellen Hollywood (6)
  4. Leonard Saltz (6)
  5. Yelena Janjigian (6)
  6. Geoffrey Ku (5)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2014 (2)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer (2)
  3. Pancreas (2)
  4. Annals of Oncology (1)
  5. Clinical Cancer Research (1)
  6. Lancet Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. Lippincott Williams & Wilkins (2)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. Oxford University Press (1)

More Publishers

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)
    Meeting Abstract

    Janjigian, Y. Y.; Tang, L. H.; Shibata, S.; Kelsen, D. P.; Segal, M.; Cheng, C.; Schwartz, G. K.; Doyle, L. A.; Shah, M. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    Journal Article

    Reidy-Lagunes, D. L. ; Vakiani, E.; Segal, M. F.; Hollywood, E. M.; Tang, L. H.; Solit, D. B.; Pietanza, M. C.; Capanu, M.; Saltz, L. B.
    Cancer (2012)

    Fulltext@MSK | Save
  • Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors
    Journal Article

    Chung, K. Y.; Saito, K.; Zergebel, C.; Hollywood, E.; Segal, M.; Saltz, L. B.
    Oncology (2011)

    Fulltext@MSK | Save
  • A phase II clinical T trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R) in patients with metastatic well differentiated neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Hollywood, E.; Segal, M.; Saltz, L.
    Pancreas (2011)

    Fulltext@MSK | Save
  • A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs)
    Meeting Abstract

    Reidy, D. L.; Hollywood, E.; Segal, M.; Saltz, L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save